Roche puts new investment “on hold”
In his interview with Welt, Daniel Steiners said Roche was reviewing all future investments in Germany because of healthcare cost-cutting policies. In his view, politicians have seriously damaged the pharmaceutical industry’s trust.
The move by one of the world’s largest drugmakers is a significant signal for Europe’s biggest economy, which is trying to attract industrial investment.
We have put all future investment decisions in Germany on hold for the time being.
A dispute over how to handle healthcare costs
Steiners argued that instead of addressing the structural problems of the statutory health insurance system, policymakers were focusing on short-term savings and placing extra burdens on industry. Germany’s proposed legislation aims to cap rapidly growing costs in the health insurance system.














